Browsing publications by Dr Ross Maxwell

Newcastle AuthorsTitleYear
Dr Britta Vormoor
Henrike Knizia
Michael Batey
Dr Ian Wilson
Dr Petra Dildey
et al.
Development of a Preclinical Orthotopic Xenograft Model of Ewing Sarcoma and Other Human Malignant Bone Disease Using Advanced In Vivo Imaging2014
Emma Haagensen
Huw Thomas
Ian Wilson
Dr Suzannah Harnor
Dr Sara Henderson
et al.
The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice2013
Dr Umar Burki
Dr Alison Blain
Dr Ian Wilson
Dr Guillaume Launay
Dr Ross Maxwell
et al.
Development of in vivo imaging techniques to determine the biodistribution of antisense oligonucleotides in dystrophin deficient muscular dystrophy2012
Emma Haagensen
Suzanne Kyle
Dr Gary Beale
Dr Ross Maxwell
Professor Herbie Newell
et al.
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition2012
Dr Sanjoy Chatterjee
Dr John Wilsdon
Dr Judith Mott
Paddy Stevenson
Dr Ross Maxwell
et al.
Final Results of Vortigern Study: CT Versus Pet-CT Based Tomotherapy Voluming and Dose Escalation in Oropharyngeal Squamous Cell Carcinoma (ISRCTN 33175361, UKCRN ID: 08/h0907/127) [meeting abstract]2011
Henrike Knizia
Michael Batey
Gilberto de Almeida
Dr Ross Maxwell
Dr Petra Dildey
et al.
Development of an orthotopic model for human malignant bone diseases in immunocompromised NOD.Cg-PrkdcscidIl2rgtmlwjl/szj (NSG) mice2010
Dr Ross Maxwell
Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates2010
Dr Ross Maxwell
John Wilson
Carbogen breathing increases prostate cancer oxygenation: A translational MRI study in murine xenografts and humans2009
Dr Ross Maxwell
[Meeting Abstract] Combretastatin activity in tumours: factors of importance2008
Dr Ross Maxwell
Preclinical Studies to Predict Efficacy of Vascular Changes Induced by Combretastatin A-4 Disodium Phosphate in Patients2008
12